| A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer (NCT03246347) | Wake Forest University Health Sciences | 2017-08-23 |
| Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer (NCT03274687) | NRG Oncology | 2017-07-28 |
| Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer (NCT03204812) | M.D. Anderson Cancer Center | 2017-07-14 |
| PSMA PET Imaging of Recurrent Prostate Cancer (NCT03204123) | Memorial Sloan Kettering Cancer Center | 2017-06-26 |
| Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer (NCT03177460) | M.D. Anderson Cancer Center | 2017-06-07 |
| 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment (NCT02673151) | Andrei Iagaru | 2017-05-20 |
| A Study Evaluating MM-310 in Patients With Solid Tumors (NCT03076372) | Merrimack Pharmaceuticals | 2017-02-22 |
| Molecular PET/MR Imaging in Vivo Validation of Biomarker for Human Prostate Cancer (NCT03451812) | Chang Gung Memorial Hospital | 2017-01-01 |
| 68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery (NCT03368547) | Jonsson Comprehensive Cancer Center | 2016-12-12 |
| Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy (NCT02940262) | Jonsson Comprehensive Cancer Center | 2016-09-15 |
| Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients (NCT02853097) | University of Southern California | 2016-06-14 |
| Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk Prostate Cancer (NCT02454517) | Fred Hutchinson Cancer Center | 2016-05-19 |
| Prostate Cancer - Localized Adenocarcinoma Proton Therapy (NCT03285815) | National Cancer Center, Korea | 2016-05-01 |
| 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer (NCT02624518) | Andrei Iagaru | 2015-11-16 |
| MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca (NCT02564549) | Virginia Commonwealth University | 2015-10-05 |
| Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors (NCT02600156) | Mayo Clinic | 2015-09-01 |
| Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel (NCT02491411) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-09-01 |
| Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223 (NCT02981797) | H. Lee Moffitt Cancer Center and Research Institute | 2015-07-22 |
| Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer (NCT02499835) | University of Wisconsin, Madison | 2015-07-01 |
| Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors (NCT02285101) | Bio-Cancer Treatment International Limited | 2014-11-01 |
| Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate (NCT02268175) | Dana-Farber Cancer Institute | 2014-10-01 |
| A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer (NCT02254746) | Centre Hospitalier Universitaire Vaudois | 2014-08-01 |
| Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer (NCT02206334) | NRG Oncology | 2014-08-01 |
| Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer (NCT02168062) | University of California, San Francisco | 2014-06-16 |
| Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer (NCT02031328) | Sunnybrook Health Sciences Centre | 2014-01-01 |
| CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer (NCT01985828) | Wake Forest University Health Sciences | 2013-11-19 |
| Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer (NCT01787331) | University of California, San Francisco | 2013-10-29 |
| Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery (NCT02603965) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2013-08-01 |
| Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy (NCT01953640) | Mayo Clinic | 2013-05-30 |
| Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer (NCT01731912) | University of Washington | 2013-05-01 |
| Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide (NCT02228265) | OHSU Knight Cancer Institute | 2013-03-12 |
| Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk Prostate Cancer (NCT01737151) | Virginia Commonwealth University | 2013-03-08 |
| Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer (NCT01786265) | M.D. Anderson Cancer Center | 2013-02-05 |
| Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer (RAD 1203) (NCT01856855) | John Fiveash, MD | 2013-02-01 |
| Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without MRI-Guided Management (NCT01838265) | University of Miami | 2012-08-01 |
| MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial (NCT01411345) | University of Miami | 2012-07-12 |
| Evaluation of Hypoxia by PET With F-Miso in Radiation Therapy of Prostate Cancer (NCT01898065) | Institut Cancerologie de l'Ouest | 2012-06-01 |
| C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma (NCT01530269) | Phoenix Molecular Imaging | 2012-04-01 |
| A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy (NCT01661166) | Abramson Cancer Center at Penn Medicine | 2012-01-01 |
| MRI-Guided Lattice Extreme Ablative Dose Radiotherapy For Prostate Cancer (NCT01411319) | University of Miami | 2011-12-27 |
| An Evaluation of Polymer Based Fiducials for Use in Imaging Patients Receiving Treatment for Prostate Cancer (NCT01478412) | John Chang, MD | 2011-12-01 |
| Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer (NCT01325311) | National Cancer Institute (NCI) | 2011-12-01 |
| Hypofractionated Image-Guided Radiotherapy For Prostate Cancer: The HEIGHT Trial (NCT01411332) | University of Miami | 2011-10-31 |
| Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer (NCT01347788) | Massachusetts General Hospital | 2011-04-01 |
| Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer (NCT01120236) | National Cancer Institute (NCI) | 2010-12-01 |
| ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma (NCT01219790) | Institut Cancerologie de l'Ouest | 2010-10-01 |
| Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01145508) | National Cancer Institute (NCI) | 2010-08-01 |
| Surgery Combined With Intensity Modulated Radiation Therapy - Image-Guided Radiation Therapy (IMRT-IGRT) in Locally-advanced Prostate Cancers (NCT01148069) | Rennes University Hospital | 2010-07-30 |
| Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel (NCT01253642) | OHSU Knight Cancer Institute | 2010-07-12 |
| Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer (NCT01352429) | Abramson Cancer Center at Penn Medicine | 2009-08-01 |
| Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy (NCT00937768) | Mayo Clinic | 2009-07-01 |
| Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation (NCT00887432) | Roswell Park Cancer Institute | 2009-04-08 |
| Patients Overexposed for a Prostate Adenocarcinoma (NCT00773656) | Assistance Publique - Hôpitaux de Paris | 2008-10-01 |
| Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer (NCT00589472) | National Cancer Institute (NCI) | 2007-11-01 |
| Phase 2 Hypofractionation Study Using Proton Beam Therapy for Prostate Adenocarcinoma (NCT01709253) | National Cancer Center, Korea | 2007-03-01 |
| Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer (NCT00536991) | Roswell Park Cancer Institute | 2006-10-01 |
| 131-I-TM-601 Study in Adults With Solid Tumors (NCT00379132) | TransMolecular | 2006-08-01 |
| Phase II Trial of SBRT + or - IMRT in Treatment of Patients With Clinically Confined Prostate Adenocarcinoma (NCT02339948) | GenesisCare USA | 2006-06-01 |
| Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer (NCT02175212) | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | 2005-11-01 |
| Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer (NCT00170157) | Mayo Clinic | 2004-06-01 |
| Trilostane for Androgen-Independent Prostate Cancer (NCT00181597) | Genzyme, a Sanofi Company | 2004-03-01 |
| Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy. (NCT00183924) | University of Southern California | 2001-03-01 |
| F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer (NCT03501940) | Andrei Iagaru | |
| Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer (NCT04377152) | University of California, San Francisco | |